Organogenesis (NASDAQ:ORGO) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Organogenesis from “sell” to “strong sell.” The broader analyst consensus is “Reduce,” with a consensus price target of $4.33.
• Third-quarter results missed expectations: the company reported a loss of $0.25 per share versus an expected $0.18 loss, while revenue of $45.46 million fell short of the $52.10 million estimate.
• Management expects to cut annual operating expenses by about $45 million, and third-quarter net product revenue rose 6% sequentially, offering potential offsets to the weak results.

Organogenesis (NASDAQ:ORGO - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other analysts have also recently issued reports on the company. Truist Financial dropped their price objective on Organogenesis from $3.00 to $2.00 and set a "hold" rating on the stock in a report on Friday, August 7th. Weiss Ratings lowered shares of Organogenesis from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, October 19th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and a consensus price target of $4.33.

Organogenesis Stock Performance

NASDAQ ORGO opened at $0.81 on Friday. Organogenesis has a twelve month low of $0.73 and a twelve month high of $7.08. The firm has a 50-day simple moving average of $1.26 and a 200 day simple moving average of $2.31. The company has a current ratio of 3.52, a quick ratio of 3.00 and a debt-to-equity ratio of 0.07.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $45.46 million for the quarter, compared to the consensus estimate of $52.10 million. Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.

Hedge Funds Weigh In On Organogenesis

A number of large investors have recently modified their holdings of ORGO. Jefferies Financial Group Inc. bought a new position in Organogenesis during the third quarter worth $233,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Organogenesis in the second quarter worth about $33,000. Waverly Advisors LLC bought a new stake in shares of Organogenesis in the second quarter valued at about $25,000. Hsbc Holdings PLC lifted its holdings in shares of Organogenesis by 167.8% during the second quarter. Hsbc Holdings PLC now owns 139,166 shares of the company's stock valued at $324,000 after acquiring an additional 87,203 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Organogenesis in the 2nd quarter valued at $57,000. 49.57% of the stock is owned by hedge funds and other institutional investors.

Key Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Management expects to reduce annual operating expenses by approximately $45 million, which could help lower costs. Third-quarter net product revenue also rose 6% from the prior quarter, signaling some sequential recovery. Article: Organogenesis: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The earnings call was characterized as showing signs of recovery alongside major setbacks; the sequential revenue improvement and cost-cutting plan offer possible offsets, but do not erase the weak quarterly results. Article: Organogenesis Earnings Call Signals Recovery Amid Major Setbacks
• Negative Sentiment: Organogenesis reported a third-quarter loss of $0.25 per share, wider than the $0.18 loss analysts expected. Revenue of $45.46 million also missed the $52.10 million consensus estimate, raising concerns about near-term performance. Article: Organogenesis Reports Third Quarter 2026 Financial Results

About Organogenesis

Organogenesis Holdings Inc is a biotechnology company that develops, manufactures and commercializes products intended to support tissue regeneration and wound healing. The company serves the advanced wound care and surgical and sports medicine markets, with a focus on therapies that help manage complex wounds and support the repair of damaged tissue.

Its product portfolio includes bioengineered skin substitutes and other biologic products, such as Apligraf, Dermagraft, NuShield, Affinity and NuCel.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.